Introduction: hain GenoType MTBDRsl is nucleic acid amplification assay based on reverse hybridization with specific oligonucleotide probes on
Introduction
Drug resistant TB has emerged as a significant global public health problem and a great challenge for TB control. Drug resistant TB has resulted from drug misuse and/or drug mismanagement. In 2014 WHO estimate 480 000 multi drug resistant (MDR) cases; Most of these cases are in India, China, Russian Federation and South Africa [1] . Extensively drug-resistant TB (XDR-TB) had been reported by 105 countries by 2015. The magnitude of XDR-TB is not small (9.7% of MDR-TB) in addition XDR-TB is an important killer of TB patients [1, 2] . Most species of mycobacteria grow slowly with generation time of 18 to 24 hours; resulting in delay of TB diagnosis by conventional methods [3] . Molecular techniques reducing turnaround time (TAT) required to detect and identify M.
tuberculosis to 1-2 days instead of several weeks in the conventional methods [4] . Extensively drug-resistant tuberculosis (XDR-TB) is defined as multi drug resistant tuberculosis MDR-TB; resistance of rifampicin and isoniazid with additional resistance to any fluoroquinolone and to at least one of three injectable drugs used for TB treatment: capreomycin, kanamycin, or amikacin [5] . In recent years several molecular methods have been developed for the diagnosis of tuberculosis and detection of drug resistance, including line probe assays [6] . Line probe assays (LPAs) are not new; nevertheless Hain Lifescience (Hain Lifescience GmbH, Germany) developed two kits of line probe assay for the detection of drug resistance, the genotype MTBDRplus and MTBDRsl [7] the later is one of the few commercially available molecular tests for detection of second line drugs [8] . MTBDRplus simultaneously detects MDR and the MTBDRsl detect the resistance of aminoglycosides/cyclic peptides, fluoroquinolones, and ethambutol through detection of mutations in the relevant genes [7] . In 2015, the Hain Lifescience developed the commercially available version 2.0 of the MTBDRsl assay and recently recommended by WHO [1] ; to date version 2.0 MTBDRsl is not supplied in Sudan. To our knowledge; in Sudan second line drug resistance and XDR susceptibility testing has never been studied before this report. Kanamycin (KM), 30μg/ml; Capreomycin (CM), 40μg/ml; Ofloxacin (Ofx), 2.0μg/ml [9] and Amikacin (AM) 40μg/ml [10] . First line Ethambutol (EMB) was added to reach the final critical concentration of 2.0μg/ml [9] . positive and false negative result were reported. This can be attributed to missed mutation that is not involved in the test strip in addition to probable cross resistance. Low sensitivity and high specificity for fluoroquinolones has been previously reported [15, 20] .
Methods
XDR: the majority of MDR (90%, 45/50) were susceptible to the all second line anti-tuberculous drugs. MTBDRsl showed very high performance (p=0.02) in detecting XDR with sensitivity of (100%) and specificity of (100%). Positive and negative predictive values were (100%) and (100%). The isolate was concordantly detected by the two methods Table1. To our knowledge; in Sudan second line drug resistance and XDR susceptibility testing has never been studied before this report. The low frequency of XDR-TB within the study cohort is within the reported frequency that was reported from many countries (0.8-15.2%) [19] . but is also this study constrained by the limited sample size. Moreover; this may reflect the imperfect reference standard currently available for this drug [17, 20] .
Conclusion
In conclusion Hain GenoType MTBDRsl showed high specificity and negative predictive values (NPVs) making it an acceptable, simple and time-saving technique for early presumptive detection of resistance to second-line anti-TB drugs in Sudan.
What is known about this topic
 The assay has moderate test sensitivity for the detection of fluoroquinolone and second-line injectable resistance, with high test specificity;
 There was significant heterogeneity in the sensitivity for the detection of kanamycin across studies, resulting in the assay being considered to be insufficient;
 Despite high pooled specificity estimates for all second-line drugs evaluated, the lower pooled sensitivity estimates mean that negative results for resistance cannot be considered to reliably rule-out resistance, as rates of falsenegative results were variable among the reported studies and quite high for the detection of resistance to kanamycin.
What this study adds
 Study evaluated the test performance in the local work situation against the local strains and their different mutations;
 Study ensures the quality of the service that is delivered by the local health system.
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